CD19 and hematologic disorder: While great strides have been made toward uncovering the pathogenesis of the cytokine-associated toxicities CRS23,24 and ICANS,25,26 which have been widely observed in clinical trials of anti-CD19 CAR-T cells for hematologic malignancies, less is known about the pathogenesis of toxicities in other settings.